Mu opioid receptor antagonists: recent developments.

ChemMedChem 2007 Nov;2(11):1552-70

Department of Medicinal Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, PA 19341, USA.

For thousands of years mu opioid agonists such as morphine have been utilized for their analgesic properties. Today, morphine and related compounds are still used as a first line therapy in the treatment of moderate to severe pain. However, despite the clear benefits of mu agonists in pain management, severe side effects such as dependence and respiratory depression are associated with use of these drugs. To date, there are only two approved mu opioid antagonists for use in the treatment of these adverse effects, that is, naloxone and naltrexone. However, many other clinical and therapeutic areas have been linked to mu opioid receptor antagonism. These include treatment of opioid induced pruritus of the skin, obesity, and Parkinson-induced tardive dyskinesia. Currently there are two compounds, N-methylnaltrexone and alvimopan, under FDA review as possible treatments for opioid induced bowel dysfunction and postoperative ileus. These compounds are of special interest as they are peripherally restricted. This attribute enables treatment of peripheral side effects induced by opioid agonists without reversal of the centrally mediated analgesia of the agonist. In this article we discuss the structural classes of mu opioid antagonists, their potential clinical applications, and review the relevant patents of the last ten years.

Download full-text PDF

Source
http://dx.doi.org/10.1002/cmdc.200700143DOI Listing
November 2007
2 Reads

Publication Analysis

Top Keywords

opioid
8
side effects
8
opioid agonists
8
opioid induced
8
opioid antagonists
8
opioid receptor
8
currently compounds
4
compounds n-methylnaltrexone
4
dyskinesia currently
4
tardive dyskinesia
4
obesity parkinson-induced
4
parkinson-induced tardive
4
n-methylnaltrexone alvimopan
4
alvimopan fda
4
induced bowel
4
bowel dysfunction
4
treatments opioid
4
review treatments
4
fda review
4
skin obesity
4

References

(Supplied by CrossRef)

Aldrich et al.
1996

2003

Williams et al.
J. Med. Chem. 1999

Krishnan-Sarin et al.
Pharmacol. Biochem. Behav. 1998

Mitch et al.
J. Med. Chem. 1993

Mendelsohn et al.
J. Med. Chem. 1993

Pastor et al.
Drug Alcohol Depend. 2005

Henry et al.
Exp. Neurol. 2001

Schmidhammer et al.
Prog. Med. Chem. 1998

Similar Publications